812 - The Potentially "Game-changing" RSV Products Available This Season
Public Health On Call
The Johns Hopkins Bloomberg School of Public Health
4.6 • 644 Ratings
🗓️ 23 October 2024
⏱️ 14 minutes
🔗️ Recording | iTunes | RSS
🧾️ Download transcript
Summary
About this episode:
Respiratory syncytial virus can be particularly dangerous for older adults and infants and this year, for the first time, there are three approved and readily available products to help prevent severe disease: A vaccine for pregnant women and people over age 65, and an antibody treatment for infants born during RSV season. In this episode: all about these products and the promise they show for dramatically reducing the number of hospitalizations and deaths from RSV this year.
Guests:
Dr. Georgina Peacock is the director of the Immunization Services Division in the National Center on Immunization and Respiratory Diseases at the CDC.
Host:
Dr. Josh Sharfstein is vice dean for public health practice and community engagement at the Johns Hopkins Bloomberg School of Public Health, a faculty member in health policy, a pediatrician, and former secretary of Maryland's Health Department.
Show links and related content:
-
Surveillance of RSV—CDC
-
Why So Many Babies Didn't Get RSV Vaccines This Winter—Public Health On Call (February, 2024)
Contact us:
Have a question about something you heard? Looking for a transcript? Want to suggest a topic or guest? Contact us via email or visit our website.
Follow us:
Transcript
Click on a timestamp to play from that location
| 0:00.0 | Welcome to Public Health On Call, a podcast from the Johns Hopkins Bloomberg School of Public Health, |
| 0:05.9 | where we bring evidence, experience, and perspective to make sense of today's leading health challenges. |
| 0:16.3 | If you have questions or ideas for us, please send an email to public health question at jh. |
| 0:21.6 | Jh.edu. |
| 0:22.6 | That's public health question at jh.u.edu for future podcast episodes. |
| 0:29.6 | This is Lindsay Smith Rogers. |
| 0:33.6 | Today, it is RSV season. |
| 0:36.6 | Dr. Georgina Peacock is the director of the Immunization |
| 0:40.5 | Services Division in the National Center on Immunization and Respiratory Diseases at the U.S. |
| 0:45.9 | Center for Disease Control and Prevention. She talks everything RSV with Dr. Josh Sharfstein, |
| 0:51.5 | including who is most at risk, what can be done to prevent infection, |
| 0:56.2 | and whether people will have access to key vaccines and antibody treatments this year. |
| 1:00.9 | Let's listen. |
| 1:02.6 | Dr. Georgina Peacock, thank you so much for joining me today on Public Health On Call to talk about RSV. |
| 1:09.3 | And let's start perhaps with a basic question. Can you remind us all |
| 1:13.7 | what RSV is? Sure. So RSV, and the long name of it is respiratory syncytial virus, is a really |
| 1:21.8 | common respiratory virus. Usually looks like the common cold. It affects the nose, throat, and lungs, but it can make |
| 1:30.3 | infants and older adults really sick. When infants and older adults get really sick with |
| 1:36.5 | RSV, what does that look like? Typically, it means they have trouble breathing, and so they need help |
| 1:43.8 | in the hospital, either with oxygen or other things that will help them get through the illness. |
| 1:50.3 | And does RSV lead to some deaths every year? |
| 1:53.6 | It does. So it can lead to deaths, both in infants and in older adults. |
... |
Please login to see the full transcript.
Disclaimer: The podcast and artwork embedded on this page are from The Johns Hopkins Bloomberg School of Public Health, and are the property of its owner and not affiliated with or endorsed by Tapesearch.
Generated transcripts are the property of The Johns Hopkins Bloomberg School of Public Health and are distributed freely under the Fair Use doctrine. Transcripts generated by Tapesearch are not guaranteed to be accurate.
Copyright © Tapesearch 2026.